WallStreetZenWallStreetZen

NASDAQ: LVTX
Lava Therapeutics Nv Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

LVTX past revenue growth

How has LVTX's revenue growth performed historically?
Company
239.31%
Industry
69.78%
Market
14.1%
LVTX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LVTX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LVTX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

LVTX earnings and revenue history

Current Revenue
$20.6M
Current Earnings
-$33.9M
Current Profit Margin
-164.5%

LVTX Return on Equity

Current Company
-33.5%
Current Industry
-33%
Current Market
188%
LVTX's Return on Equity (-33.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when LVTX announces earnings.

LVTX Return on Assets

Current Company
-23.7%
Current Industry
0.2%
LVTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

LVTX Return on Capital Employed

Current Company
-26.27%
Current Industry
12.2%
LVTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

LVTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
LVTX$21.08M-$33.84M-$34.68M+112.47%N/A
TSHA$7.21M-$126.34M-$133.53MN/AN/A
QNCX$0.00-$42.05M-$42.27MN/AN/A
RFL-$1.59M-$13.42M-$11.97MN/AN/A
PMCB$0.00-$5.61M-$5.61MN/AN/A
View Top Biotech Stocks

Lava Therapeutics Nv Earnings & Revenue FAQ

What were LVTX's earnings last quarter?

On Invalid Date, Lava Therapeutics Nv (NASDAQ: LVTX) reported Q4 2022 earnings per share (EPS) of -$0.61, up 153.56% year over year. Total Lava Therapeutics Nv earnings for the quarter were -$15.95 million. In the same quarter last year, Lava Therapeutics Nv's earnings per share (EPS) was -$0.24.

If you're new to stock investing, here's how to buy Lava Therapeutics Nv stock.

What was LVTX's earnings growth in the past year?

As of Q2 2023, Lava Therapeutics Nv's earnings has grown year over year. Lava Therapeutics Nv's earnings in the past year totalled -$34.68 million.

What was LVTX's revenue last quarter?

On Invalid Date, Lava Therapeutics Nv (NASDAQ: LVTX) reported Q4 2022 revenue of $2.81 million up 131.85% year over year. In the same quarter last year, Lava Therapeutics Nv's revenue was $1.21 million.

What was LVTX's revenue growth in the past year?

As of Q2 2023, Lava Therapeutics Nv's revenue has grown 239.31% year over year. This is 169.54 percentage points higher than the US Biotechnology industry revenue growth rate of 69.78%. Lava Therapeutics Nv's revenue in the past year totalled $21.08 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.